FDAnews
www.fdanews.com/articles/205136-who-considers-mercks-antiviral-covid-19-pill-for-mild-and-moderate-cases

WHO Considers Merck’s Antiviral COVID-19 Pill for Mild and Moderate Cases

November 2, 2021

The World Health Organization (WHO) wants Merck to provide additional data on its investigational COVID-19 antiviral, molnupiravir, co-developed with Ridgeback Biotherapeutics.

The WHO is considering releasing guidance in the coming weeks on administering the oral medication for mild and moderate COVID-19 infections.  

In the U.S., an FDA advisory committee is set to consider molnupiravir on Nov. 30 and offer its recommendation on whether the drug should be authorized for emergency use.

View today's stories